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caNanoLab Goal
To provide nanotechnology resources to 
facilitate data sharing in the research 
community to expedite and validate the use 
of nanomaterials in biomedicine
Example Nanotechnology User Scenario
An existing drug used to target cancer causes significant side effects.  
Can nanomaterial-assisted targeted delivery increase efficacy and  
reduce side effects?
• Identify and synthesize a nanomaterial delivery system that:
• Is biocompatible and has a long half-life
• Is designed to effectively target the cancer cells 
• Is multi-functional (imaging, therapeutic, targeting agents on the same vehicle)
• Perform physico-chemical characterizations (size, zeta potential) to validate 
nanomaterial synthesis and determine the stability of the particle
• Perform in vitro characterizations (cytotoxicity, immune cell function) to 
determine the toxicity and effectiveness of the nanomaterial formulation in 
model cell lines. Compare the nanomaterial delivery system to the drug alone 
and the nanomaterial alone.
• Perform in vivo characterizations (pharmacokinetics, toxicology) on 
established animal tumor models. Efficacy, dosing, and side effects of the 
current drug dosing protocol are compared with the targeted nanomaterial 
delivery system.
caNanoLab Overview
•caNanoLab is a portal designed to 
facilitate data sharing in the research 
community to expedite and validate the 
use of nanomaterials in biomedicine  
•caNanoLab provides support for the 
annotation of nanomaterials with 
composition information, physico-
chemical and in vitro characterizations   
(in vivo coming soon), protocols, and 
publications
•caNanoLab leverages and extends 
concepts from the NCI’s Enterprise 
Vocabulary Services (EVS) and the 
NanoParticle Ontology (NPO)
•caNanoLab is engineered to enable 
data sharing in a semantically 
interoperable fashion in the spirit of the 
NCI cancer Biomedical Informatics Grid 
(caBIG®) program
Current Version: caNanoLab 1.5.1
http://cananolab.nci.nih.gov
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•Composition information includes: 
nanomaterial entities, functionalizing 
entities, and chemical associations
•A nanomaterial entity is the base 
nanomaterial (e.g. dendrimer) and 
composing elements (e.g. core)
•Nanomaterial entity types (e.g. 
dendrimer) have different 
composition properties (e.g. branch, 
generation)
•Functionalizing entities give the 
material the intended application (e.g. 
small molecule)
•Chemical associations represent the 
linkage and bond types between 
material components
•Supports the formulation of complex 
nanomaterials (e.g. liposome 
encapsulated in a quantum dot) 
Dendrimer Composition 
caNanoLab Composition Concepts
Characterizations:
Physico-Chemical
•Physico-Chemical Characterizations 
describe the material and structural 
properties of a nanomaterial
•Nanomaterials are polydisperse and 
exhibit diverse physico-chemical 
properties based on experimental 
conditions (e.g. ph, temperature, 
solvent) or applied 
instruments/techniques  (e.g. 
Dynamic Light Scattering)
•Physico-Chemical Characterizations 
(e.g. size, shape) have a direct 
impact on biological interactions
Molecular Weight 
caNanoLab Physico-Chemical 
Characterization Concepts
Characterizations:
In Vitro
Coagulation
caNanoLab In Vitro
Characterization Concepts
•In Vitro Characterizations determine 
the effect of nanomaterials on 
cultured cells or tissues
•In Vitro Characterizations test a 
nanomaterial’s binding, 
pharmacology, and other properties 
monitored by cellular and molecular 
biology methods
•In Vitro Characterizations also 
determine a nanomaterial’s blood 
contact properties, interactions with 
cellular-level components, and 
therapeutic and/or diagnostic 
functionality
Characterizations:
In Vivo (Coming Soon)
•In Vivo Characterizations determine the 
effect of the nanomaterial on living 
organisms 
•In Vivo Characterizations include 
animal information, treatment 
information, pharmacokinetics, and 
toxicology and are not specific to 
nanomaterials
•In Vivo Characterization concepts are 
derived from the CDISC SEND (v2.3) and 
SDTM (v3.2.1) standards for animal tox 
studies and human clinical trials 
pharmacokinetics, respectively
•Support for In Vivo Characterizations 
will include interfaces to NBIA (Images) 
and caMOD (Animal Models)
Pharmacokinetics
caNanoLab In Vivo
Characterization Concepts
Publications
•caNanoLab allows users to search and 
submit Publications and other types of 
Reports
•Samples can be associated with 
multiple Publications but can be 
submitted without Samples
•Auto-completion has been implemented 
for PubMed articles leveraging 
PubMed’s HTTP API for retrieving 
publication information in XML format
•caNanoLab provides access to 1000+ 
abstracts published by the NCI’s 
Nanotechnology Alliance 
Publication Search
Publication Search Results
Protocols
•caNanoLab allows users to submit 
Protocols for characterization, safety, 
radiolabeling, sample preparation, and 
other types of protocols
•Protocols can be associated with 
Characterizations but can be submitted 
without Characterizations
•Multiple versions of Protocols can be 
submitted
•caNanoLab provides access to 
protocols from the NCI 
Nanotechnology Characterization 
Laboratory (NCL)
Protocol Search Results
NCL CFU-GM Protocol
Search Facilities
•caNanoLab provides a basic search and advanced search allowing users to perform 
range queries
•caNanoLab provides grid services to support access to information via server-side 
Application Programming Interfaces (APIs) 
•The cancer Open Biomedical Resources (caOBR) ontology search facility and Grid 
Summary Search (GSS) iPhone App leverages caNanoLab grid services to retrieve 
caNanoLab data from the Nanoparticle Ontology (NPO)
Advanced Search caOBR Ontology Search GSS iPhone App
•Collaboration Group Management
• Allows users to create collaboration groups 
and assign users to participate in 
collaboration groups
• Allows the data owner to assign samples, 
publications, and protocols to collaboration 
groups
•Transfer of Ownership
• Allows an administrator to transfer 
ownership of a sample, publication, or 
protocol
•Data Curation Management
• Allows users to submit data for review and 
consideration for public dissemination
• Allows the data curator to review user 
submitted data and make publically 
available  
•Data Availability Metrics
• Allows users to obtain metrics on the 
completeness of submitted data
• Metrics for data completeness are based 
on a mapping of submitted data to 
caNanoLab supported data and the 
MinChar standard 
(http://characterizationmatters.org/)
caNanoLab 1.5.2
caNanoLab 1.5.2        
Available November 2010
Collaboration Group Access to Sample
View Data Availability Metrics
caNanoLab Future Features
•Support for study information and outcomes
•Continued support for nanotechnology 
standards
• Validate/import/export of nano-TAB
• NCI Enterprise level services supporting 
nanomaterials and characterizations
•Implementation of in vivo characterizations
• Support for pharmacokinetics and 
toxicology
• Interface to the NCI’s National Biomedical 
Imaging Archive (NBIA) for in vivo images
• Interface to the NCI’s cancer Model 
Organism Database (caMOD) for animal 
model information 
•Support for Structure-Activity-Relationships
• Interface with 3D modeling tools 
•Advanced search, visualization, and analysis
• Integration with GenePattern
•Implementation of grid-level security
National Biomedical Imaging Archive
Cancer Model Organism Database
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